Sanofi Terminates Pompe Disease Drug Agreement With Maze Therapeutics Following FTC Opposition
12/12 04:56
(RTTNews) - Sanofi (SNYNF, SNY) said it has decided to terminate a licensing agreement with U.S. biotech Maze Therapeutics for an investigational Pompe disease treatment candidate. This decision comes in response to a challenge raised by the U.S. Federal Trade Commission regardin...